Trial · NCT02908685
Results by group88
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 88
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 1: Selected Part 2 Dose of Risdiplam for Participants With a Body Weight (BW) of >/=20kg | Part 1: All Risdiplam | 5 | milligram (mg) | ||
| Part 1: Selected Part 2 Dose of Risdiplam for Participants With BW of <20kg | Part 1: All Risdiplam | 0.25 | milligram/kilogram (mg/kg) | ||
| Part 2: Change From Baseline in the Total Motor Function Measure 32 (MFM-32) Total Score at Month 12 | Part 2: Risdiplam | 1.36 | 95% Confidence Interval 0.61 to 2.11 | Scores on a Scale | |
| Part 2: Change From Baseline in the Total Motor Function Measure 32 (MFM-32) Total Score at Month 12 | Part 2: Placebo | -0.19 | 95% Confidence Interval -1.22 to 0.84 | Scores on a Scale | |
| Part 2: Percentage of Participants With Marked Improvement (Defined as >= 3) in the Total Motor Function Measure (MFM32) Score at Month 12 | Part 2: Risdiplam | 38.3 | 95% Confidence Interval 28.94 to 47.58 | Percentage of Participants | |
| Part 2: Percentage of Participants With Marked Improvement (Defined as >= 3) in the Total Motor Function Measure (MFM32) Score at Month 12 | Part 2: Placebo | 23.7 | 95% Confidence Interval 12.03 to 35.43 | Percentage of Participants | |
| Part 2: Change From Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12 | Part 2: Risdiplam | 1.61 | 95% Confidence Interval 1.00 to 2.22 | Scores on a Scale | |
| Part 2: Change From Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12 | Part 2: Placebo | 0.02 | 95% Confidence Interval -0.83 to 0.87 | Scores on a Scale | |
| Part 2: Change From Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12 | Part 2: Risdiplam | 0.95 | 95% Confidence Interval 0.29 to 1.61 | Scores on a Scale | |
| Part 2: Change From Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12 | Part 2: Placebo | 0.37 | 95% Confidence Interval -0.54 to 1.28 | Scores on a Scale | |
| Part 2: Change From Baseline in Forced Vital Capacity (FVC) at Month 12 in Participants Aged 6-25 Years | Part 2: Risdiplam | -5.16 | 95% Confidence Interval -7.93 to -2.39 | Percentage Predicted | |
| Part 2: Change From Baseline in Forced Vital Capacity (FVC) at Month 12 in Participants Aged 6-25 Years | Part 2: Placebo | -3.11 | 95% Confidence Interval -6.59 to 0.74 | Percentage Predicted | |
| Part 2: Change From Baseline in the Caregiver-Reported SMA Independence Scale (SMAIS) Total Score at Month 12 | Part 2: Risdiplam | 1.65 | 95% Confidence Interval 0.66 to 2.63 | Scores on a Scale | |
| Part 2: Change From Baseline in the Caregiver-Reported SMA Independence Scale (SMAIS) Total Score at Month 12 | Part 2: Placebo | -0.91 | 95% Confidence Interval -2.23 to 0.42 | Scores on a Scale | |
| Part 2: Percentage of Participants Rated by Clinicians as Improved in the Clinical Global Impression of Change (CGI-C) Scale Ratings at Month 12 | Part 2: Risdiplam | 47.5 | 95% Confidence Interval 38.15 to 56.86 | Percentage of Participants | |
| Part 2: Percentage of Participants Rated by Clinicians as Improved in the Clinical Global Impression of Change (CGI-C) Scale Ratings at Month 12 | Part 2: Placebo | 40.0 | 95% Confidence Interval 26.77 to 53.23 | Percentage of Participants | |
| Part 2: Percentage of Participants Who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM-32) Score at Month 12 | Part 2: Risdiplam | 69.6 | 95% Confidence Interval 60.72 to 78.41 | Percentage of Participants | |
| Part 2: Percentage of Participants Who Achieve Stabilization or Improvement (Defined as >= 0) in the Total Motor Function Measure (MFM-32) Score at Month 12 | Part 2: Placebo | 54.2 | 95% Confidence Interval 40.68 to 67.80 | Percentage of Participants | |
| Part 2: Percentage of Participants Who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM-32 Score at Month 12 | Part 2: Risdiplam | 28.7 | 95% Confidence Interval 20.65 to 37.88 | Percentage of Participants | |
| Part 2: Percentage of Participants Who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM-32 Score at Month 12 | Part 2: Placebo | 16.9 | 95% Confidence Interval 8.44 to 28.97 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02908685/results